These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
You may also like
Latest News
Red Cat CEO Jeff Thompson Unveils Company’s Vision For The Future Of Drone Technology
Red Cat Holdings Inc. (NASDAQ: RCAT) is a drone technology company that integrates robotic ...
Latest News
RH Shares Tank Following Underwhelming Third Quarter, Analysts Weigh In
Shares of RH (NYSE: RH) tanked in early trading on Friday, after the ...
Latest News
As US Debt Crisis Deepens, ‘Rich Dad Poor Dad’ Author Robert Kiyosaki Warns Of Looming Economic Peril: ‘America Is In Serious Trouble Financially’
The U.S. has witnessed a dramatic spike in its national debt, with an increase ...
